Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
INmune Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
INMB
Nasdaq
8731
http://www.inmunebio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for INmune Bio Inc
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
- Apr 8th, 2024 12:00 pm
INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 2:20 pm
INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Mar 31st, 2024 12:19 pm
INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements
- Mar 29th, 2024 9:31 pm
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
- Mar 28th, 2024 8:01 pm
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
- Mar 26th, 2024 8:01 pm
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
- Mar 13th, 2024 12:00 pm
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
- Mar 5th, 2024 1:00 pm
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 12th, 2024 2:00 pm
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
- Feb 6th, 2024 2:00 pm
Insiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the company
- Feb 4th, 2024 1:44 pm
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
- Jan 30th, 2024 1:00 pm
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
- Jan 16th, 2024 1:30 pm
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
- Jan 2nd, 2024 1:00 pm
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
- Dec 18th, 2023 9:01 pm
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
- Nov 29th, 2023 1:00 pm
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
- Nov 27th, 2023 1:00 pm
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
- Nov 17th, 2023 1:15 pm
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
- Nov 15th, 2023 2:00 pm
INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Call Transcript
- Nov 2nd, 2023 2:11 pm
Scroll